Abstract
One of the greatest breakthroughs in ophthalmology occurred only ten years ago following the first publication of the use of intravitreal bevacizumab to treat choroidal
neovascularisation.1 Since then the use of anti-VEGF agents bevacizumab, ranibizumab and aflibercept has spread on a massive scale throughout the world and patients are benefiting from sight-saving therapy for diseases which previously had limited or no effective therapy.
Sajjad Mahmood. (2016) Editorial Anti-VEGF Therapy: Proactive or Reactive?, Pakistan Journal of Ophthalmology, Volume 32, Issue 1.
-
Views
783 -
Downloads
56
Article Details
Volume
Issue
Type
Language
Received At
Accepted At
